

COVID-19 Pneumonia

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

Trial Status
Completed

Trial Runs In
9 Countries

Trial Identifier
NCT04320615 2020-001154-22
WA42380

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19 pneumonia.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT04320615 2020-001154-22 WA42380
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
